TABLE 4.
Serum antibody responses after ingestion of high-dose vaccine, lower-dose vaccine, or buffer placebo
| Antibody | No. (%) of recipients responding to:
|
Geometric mean peak reciprocal titer in response to:
|
||||
|---|---|---|---|---|---|---|
| Placebo | Vaccine
|
Placebo | Vaccine
|
|||
| Lower dose | High dose | Lower dose | High dose | |||
| Anti-LPS IgA | 7 (18) | 23 (59) | 30 (77) | 38 | 168 | 262 |
| Anti-LPS IgGa | 0 (0) | 18 (46) | 19 (49) | 60 | 207 | 197 |
| Anti-LPS IgM | 5 (13) | 16 (41) | 27 (69) | 47 | 113 | 190 |
| Anti-H antigen IgA | 0 (0) | 13 (33) | 26 (67) | 22 | 44 | 80 |
| Anti-H antigen IgG | 1 (3) | 11 (28) | 16 (41) | 91 | 134 | 182 |
| Anti-H antigen IgM | 4 (10) | 9 (23) | 13 (33) | 25 | 45 | 38 |
| Anti-Vi antigen IgA | 0 (0) | 3 (8) | 3 (8) | 15 | 20 | 20 |
| Anti-Vi antigen IgG | 0 (0) | 0 (0) | 0 (0) | 14 | 15 | 16 |
| Anti-Vi antigen IgM | 0 (0) | 1 (3) | 0 (0) | 12 | 13 | 13 |
a
Anti-LPS IgG data were from a secondary analysis (see the text).